EWTX — Edgewise Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710072 ·
Last close
$39.06
Market Cap
$4.24B
52W High
$48.51
52W Low
$14.25
ADV30
1,538,293
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -61,943,000 | -57,327,000 | 479,688,000 | 72,319,000 | 31,611,000 |
| Mar 2026 | 0 | — | -54,115,000 | -49,013,000 | 518,522,000 | 33,211,000 | 25,319,000 |
| Dec 2025 | 0 | — | -55,979,000 | -50,216,000 | 552,603,000 | 61,148,000 | 30,346,000 |
| Sep 2025 | 0 | — | -46,858,000 | -40,666,000 | 583,466,000 | 46,003,000 | 24,819,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,380,000
Investing CF
$166,401,000
Financing CF
$20,894,000
CapEx
$-454,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.85
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-652,711,000
Inventory
—
Receivables
—
ST Investments
$388,390,000
EBIT TTM
$-218,895,000
Pretax Income TTM
$-197,222,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -191,406,000 | -167,795,000 | 552,603,000 | 30,346,000 | 522,257,000 | -143,816,000 |
| Dec 2024 | 0 | -158,832,000 | -133,813,000 | 486,817,000 | 27,601,000 | 459,216,000 | -109,028,000 |
| Dec 2023 | 0 | -114,357,000 | -100,163,000 | 340,035,000 | 21,205,000 | 318,830,000 | -91,948,000 |
| Dec 2022 | 0 | -71,658,000 | -67,640,000 | 367,101,000 | 20,385,000 | 346,716,000 | -52,635,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-176,010,000
OpCashFlow TTM
—
Assets (Latest)
$518,522,000
Forward EPS
$-1.82
Max Pain — expiry 2026-10-16
max pain strike: $40.00 · spot: $39.06 · call oi: 3,218 · put oi: 3,441Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | $35.83 | — |
| BGM | BGM Group Ltd. | $4.09B | $10.75 | — |
| ABCL | AbCellera Biologics Inc. | $4.07B | $12.55 | — |
| TNGX | Tango Therapeutics, Inc. | $4.01B | $23.81 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.61B | $82.37 | — |
News headlines (Yahoo Finance, 1h cache)
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
2026-10-08 12:00 · Yahoo
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
2026-10-03 03:11 · Yahoo
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
2026-09-25 17:42 · Yahoo
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
2026-09-22 11:00 · Yahoo
Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-18 15:46 · Yahoo
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
2026-07-13 12:30 · Yahoo
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
2026-07-13 12:30 · Yahoo
Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarr
2026-08-17 14:32 · Yahoo
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
2026-10-02 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.